Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alberto Ferrarin
Observed names:
A. Ferrarin,
Ferrarin, Alberto
Institutions:
Fondazione IRCCS Istituto Nazionale dei Tumori,
Politecnico di Milano
Observed institutions:
Fondazione IRCCS Istituto Nazionale dei Tumori,
Politecnico di Milano
ORCID:
0009-0004-8915-5750
Observed ORCID:
0009-0004-8915-5750
OpenAlex ID:
A5093019344
MetaLung: Towards a Secure Architecture for Lung Cancer Patient Care on the Metaverse
2023
·
Michele Zanitti
, Mieszko Ferens
, et al.
·
IEEE International Conference on Metaverse Computing, Networking and Applications (MetaCom)
·
14
PDF
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
2026
·
Arsela Prelaj
, Vanja Miskovic
, et al.
·
Nature Medicine
·
4
Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer
2025
·
L. Provenzano
, M. Favali
, et al.
·
ESMO Real World Data and Digital Oncology
·
4
PDF
Clinician expertise and prompt engineering enhance cancer information extraction in electronic health records by small language models
2026
·
Federica Corso
, Vittoria Peppoloni
, et al.
·
Communications Medicine
·
3
PDF
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer
2026
·
Arsela Prelaj
, Leonardo Provenzano
, et al.
·
npj Precision Oncology
·
2
PDF
Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients.
2025
·
Federica Corso
, Laura Mazzeo
, et al.
·
Journal of Clinical Oncology
·
2
117P Predicting immunotherapy response in non-small cell lung cancer using a foundation model for tabular data and real-world clinical evidence: Insights from APOLLO11 study
2025
·
C.M. Licciardello
, A. Ferrarin
, et al.
·
ESMO Real World Data and Digital Oncology
·
1
PDF
P1.17.44 Multiomic Interaction Among Host and Tumor Immunity for Chemo De-Escalation. People Phase II Trial, First Line Pembrolizumab in Low PD-L1 NSCLC
2025
·
L.M. Invernizzi
, G. Farhikhteh
, et al.
·
Journal of Thoracic Oncology
·
1
P1.17.30 Deep Learning-Based Lung Tumor Segmentation for Survival Prediction in NSCLC Patients
2025
·
M. Favali
, L. Provenzano
, et al.
·
Journal of Thoracic Oncology
·
1
Multimodal AI using host, tumor, and ghost biomarker for predicting immunotherapy efficacy in NSCLC.
2025
·
Vanja Miscovic
, Marta Brambilla
, et al.
·
Journal of Clinical Oncology
·
1
4254P Early-on-treatment neutrophil dynamics predict first-line therapy outcome in advanced NSCLC: An explainable machine learning survival analysis
2026
·
C. Silvestri
, A. Rigamonti
, et al.
·
Annals of Oncology
214P Multidimensional evaluation framework for clinical AI agents supporting I-line immunotherapy decision-making in advanced NSCLC
2026
·
R. Romanò
, F. Corso
, et al.
·
Annals of Oncology
205P A human-in-the-loop approach for clinical trial matching in lung cancer
2026
·
V. Peppoloni
, G. Leone
, et al.
·
Annals of Oncology
358P Multimodal [18F]FDG-PET/CT foundation model framework for 24-month overall survival prediction in immunotherapy-treated advanced NSCLC
2026
·
B. Guirges
, L. Provenzano
, et al.
·
Annals of Oncology
194P LLM-generated narratives improve oncologists' understanding of AI-based immunotherapy response prediction in metastatic NSCLC
2026
·
C.M. Licciardello
, G. Di Virgilio
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
124P Multidimensional evaluation of AI agents: Reasoning quality and clinical effectiveness in real-world I line decision-making for NSCLC
2026
·
R. Romanò
, M. Alipoor
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
199P Assessing the role of XAI in clinical decision-making for immunotherapy response in NSCLC: Findings from the I3LUNG study
2026
·
G. Di Virgilio
, C.M. Licciardello
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
353P The preservation gap: The NAT-clinical framework for governing clinical large language models across updates
2026
·
S. Natangelo
, R. Romanò
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
341P Transported survival risk models in multicenter oncology: Separating unrecoverable transfers from method failure
2026
·
L. Lerma
, A. Ferrarin
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
359P DAISY: Guidelines for preparing AI-ready CT scans
2026
·
M. Favali
, B. Guirges
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
342P Combining agentic AI and neuro-symbolic reasoning for clinical trial matching
2026
·
V. Peppoloni
, G. Leone
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
MO13.06: A Triage-Aware Neuro-Symbolic Platform for Safe Lung Cancer Trial Matching
2026
·
V. Peppoloni
, G. Leone
, et al.
·
Journal of Thoracic Oncology
A triage-aware neuro-symbolic approach for clinical trial matching in oncology: Real-world validation in lung and genitourinary cancer.
2026
·
Vittoria Peppoloni
, Giuseppe Leone
, et al.
·
Journal of Clinical Oncology
97P Multimodal AI models integrating clinical and CT imaging data to predict survival outcomes in immunotherapy-treated NSCLC: Results from the multicentric APOLLO11 study
2026
·
V. Miskovic
, C.M. Licciardello
, et al.
·
ESMO Open
474P Low-cost translational multimodal biomarkers to identify poor outcomes to immunotherapy in advanced NSCLC
2026
·
V. Miskovic
, C.M. Licciardello
, et al.
·
ESMO Open
Show more works
View as search
Works count:
42
Citation count:
33
H-index:
3
I10-index:
1
Year
Topic
Type